Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer
Status:
Completed
Trial end date:
2020-03-18
Target enrollment:
Participant gender:
Summary
This is a phase Ib study designed to evaluate the safety and toxicity of the combination of
Alisertib and MLN0128 in patients with advanced solid tumors with an expansion cohort in
patients with previously treated metastatic TNBC.